Drugs / Pleconaril
Pleconaril
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00394914 | Aug 2006 → Apr 2007 | Picornaviridae infectious disease, asthma, common cold | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00031512 | Jun 2001 → Sep 2010 | enterovirus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04838145 Comparator | Aug 2018 → Oct 2020 | enterovirus infectious disease, type 1 diabetes mellitus | Oslo University Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pleconaril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00394914 ↗ |
| Known as | Pleconarilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL29609 ↗ |
| Known as | VP63843 | “Pleconaril (VP63843)” NCT00031512 ↗ |
| Known as | WIN 63843 | ChEMBL registry synonym — accepted as the source's own label CHEMBL29609 ↗ |
| Modality | Small molecule | — CHEMBL29609 ↗ |
| Route | Oral | “5 mg/kg /dose oral every 8 hours” NCT00031512 ↗ |